CD274 and head and neck squamous cell carcinoma: The phase III JAVELIN Head and Neck 100 trial tested adding the PD-L1 inhibitor avelumab to standard chemoradiotherapy for locally advanced HNSCC, but found no improvement in progression-free survival (PFS) or overall survival.